Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Anemia

  Free Subscription


Articles published in Am J Kidney Dis

Retrieve available abstracts of 19 articles:
HTML format
Text format



Single Articles


    February 2017
  1. GUPTA N, Wish JB
    Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
    Am J Kidney Dis. 2017 Feb 24. pii: S0272-6386(17)30110.
    PubMed     Text format     Abstract available


    June 2016
  2. SHEPSHELOVICH D, Rozen-Zvi B, Avni T, Gafter U, et al
    Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.
    Am J Kidney Dis. 2016 Jun 16. pii: S0272-6386(16)30125.
    PubMed     Text format     Abstract available


    April 2016
  3. RATCLIFFE LE, Thomas W, Glen J, Padhi S, et al
    Diagnosis and Management of Iron Deficiency in CKD: A Summary of the NICE Guideline Recommendations and Their Rationale.
    Am J Kidney Dis. 2016;67:548-58.
    PubMed     Text format     Abstract available


    March 2016
  4. HABBIG S, Bergmann C, Weber LT
    Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH.
    Am J Kidney Dis. 2016;67:532-3.
    PubMed     Text format    


    February 2016
  5. PROVENZANO R, Besarab A, Wright S, Dua S, et al
    Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
    Am J Kidney Dis. 2016 Feb 1. pii: S0272-6386(16)00005.
    PubMed     Text format     Abstract available


    January 2016
  6. BRIGANDI RA, Johnson B, Oei C, Westerman M, et al
    A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Am J Kidney Dis. 2016 Jan 27. pii: S0272-6386(15)01495.
    PubMed     Text format     Abstract available


    December 2015
  7. LEE J, Imani P, Geer J, Braun M, et al
    The Pharmacokinetics of Intradialytic Administration of Eculizumab in an Infant.
    Am J Kidney Dis. 2015;66:1105-6.
    PubMed     Text format    


    November 2015
  8. VAZIRI ND, Kalantar-Zadeh K, Wish JB
    New Options for Iron Supplementation in Maintenance Hemodialysis Patients.
    Am J Kidney Dis. 2015 Nov 23. pii: S0272-6386(15)01322.
    PubMed     Text format     Abstract available


    September 2015
  9. BROOKHART MA, Freburger JK, Ellis AR, Winkelmayer WC, et al
    Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients.
    Am J Kidney Dis. 2015 Sep 15. pii: S0272-6386(15)01061.
    PubMed     Text format     Abstract available


  10. BONOMINI M, Del Vecchio L, Sirolli V, Locatelli F, et al
    New Treatment Approaches for the Anemia of CKD.
    Am J Kidney Dis. 2015 Sep 12. pii: S0272-6386(15)01059.
    PubMed     Text format     Abstract available


    August 2015
  11. RIGOTHIER C, Delmas Y, Roumenina LT, Contin-Bordes C, et al
    Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAlambda Antibody.
    Am J Kidney Dis. 2015;66:331-6.
    PubMed     Text format     Abstract available


    July 2015
  12. ARDISSINO G, Possenti I, Tel F, Testa S, et al
    Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update.
    Am J Kidney Dis. 2015;66:172-3.
    PubMed     Text format    


  13. WAGNER LA, Tata AL, Fink JC
    Patient safety issues in CKD: core curriculum 2015.
    Am J Kidney Dis. 2015;66:159-69.
    PubMed     Text format    


  14. WILHELM-LEEN ER, Winkelmayer WC
    Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
    Am J Kidney Dis. 2015;66:69-74.
    PubMed     Text format     Abstract available


    June 2015
  15. BU F, Meyer NC, Zhang Y, Borsa NG, et al
    Soluble c5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome.
    Am J Kidney Dis. 2015;65:968-9.
    PubMed     Text format    


    May 2015
  16. NORIS M, Remuzzi G
    Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015.
    Am J Kidney Dis. 2015 May 29. pii: S0272-6386(15)00732.
    PubMed     Text format    


  17. WINKELMAYER WC, Chang TI, Mitani AA, Wilhelm-Leen ER, et al
    Longer-term Outcomes of Darbepoetin Alfa Versus Epoetin Alfa in Patients With ESRD Initiating Hemodialysis: A Quasi-experimental Cohort Study.
    Am J Kidney Dis. 2015 May 2. pii: S0272-6386(15)00532.
    PubMed     Text format     Abstract available


    April 2015
  18. FISHBANE S, Shah HH
    The emerging role of biosimilar epoetins in nephrology in the United States.
    Am J Kidney Dis. 2015;65:537-42.
    PubMed     Text format     Abstract available


    March 2015
  19. WARADY BA, Abraham AG, Schwartz GJ, Wong CS, et al
    Predictors of Rapid Progression of Glomerular and Nonglomerular Kidney Disease in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort.
    Am J Kidney Dis. 2015 Mar 12. pii: S0272-6386(15)00090.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Anemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: